{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:50Z","timestamp":1793725910793,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.waojou.2023.100780","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T01:14:26Z","timestamp":1684372466000},"page":"100780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5564-5621","authenticated-orcid":false,"given":"Tobias","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Capitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"L\u00f6wenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.waojou.2023.100780_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","article-title":"Epidemiology and differential diagnosis of nasal polyps","volume":"27","author":"Chaaban","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.waojou.2023.100780_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"issue":"S29","key":"10.1016\/j.waojou.2023.100780_bib3","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.waojou.2023.100780_bib4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","article-title":"Endotype-driven care pathways in patients with chronic rhinosinusitis","volume":"141","author":"Bachert","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.waojou.2023.100780_bib5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.waojou.2023.100780_bib6","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"issue":"10209","key":"10.1016\/j.waojou.2023.100780_bib7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.waojou.2023.100780_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100780_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100780_bib10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.waojou.2023.100780_bib11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2023.100780_bib12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00405-021-07019-6","article-title":"Cross-cultural adaptation and validation of the 22-item sinonasal outcome test (SNOT-22) in German-speaking patients: a prospective, multicenter cohort study","volume":"279","author":"Albrecht","year":"2022","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02730-2021","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"59","author":"Reddel","year":"2022","journal-title":"Eur Respir J"},{"issue":"5 Suppl","key":"10.1016\/j.waojou.2023.100780_bib14","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jaci.2006.09.005","article-title":"Rhinosinusitis: developing guidance for clinical trials","volume":"118","author":"Meltzer","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100780_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00405-018-5210-2","article-title":"Olfactory dysfunction: properties of the Sniffin' Sticks Screening 12 test and associations with quality of life","volume":"276","author":"Hinz","year":"2019","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100780_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100780_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00151829-200504060-00007","article-title":"Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey","volume":"4","author":"Shedden","year":"2005","journal-title":"Treat Respir Med"},{"issue":"3","key":"10.1016\/j.waojou.2023.100780_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00405-006-0173-0","article-title":"Normative data for the \"Sniffin' Sticks\" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects","volume":"264","author":"Hummel","year":"2007","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100780_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jaci.2013.02.002","article-title":"Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis","volume":"131","author":"Tan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-019-1065-3","article-title":"Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials","volume":"20","author":"Xiong","year":"2019","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.waojou.2023.100780_bib21","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.waojou.2023.100780_bib22","first-page":"CD013513","article-title":"Biologics for chronic rhinosinusitis","volume":"3","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.waojou.2023.100780_bib23","first-page":"435","article-title":"Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps","volume":"60","author":"Haxel","year":"2022","journal-title":"Rhinology"},{"issue":"4","key":"10.1016\/j.waojou.2023.100780_bib24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","article-title":"Dupilumab (Dupixent((R))) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany","volume":"280","author":"Jansen","year":"2023","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12948-022-00171-2","article-title":"Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life","volume":"20","author":"Nettis","year":"2022","journal-title":"Clin Mol Allergy"},{"issue":"2","key":"10.1016\/j.waojou.2023.100780_bib26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"van der Lans","year":"2022","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.waojou.2023.100780_bib27","article-title":"Effectiveness of dupilumab in the treatment of patients with uncontrolled severe CRSwNP: a \"Real-Life\" observational study in naive and post-surgical patients","volume":"12","author":"Ottaviano","year":"2022","journal-title":"J\u00a0Personalized Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12890-022-02046-3","article-title":"Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP","volume":"22","author":"Minagawa","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.waojou.2023.100780_bib29","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.waojou.2023.100780_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11882-020-00981-x","article-title":"A\u00a0TRiP through the roles of transient receptor potential cation channels in type 2 upper airway inflammation","volume":"21","author":"Backaert","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"issue":"7","key":"10.1016\/j.waojou.2023.100780_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/00016489.2012.656764","article-title":"Olfactory dysfunction in seasonal and perennial allergic rhinitis","volume":"132","author":"Becker","year":"2012","journal-title":"Acta Otolaryngol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100780_bib32","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.waojou.2023.100780_bib33","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.4049\/jimmunol.162.5.2477","article-title":"Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells","volume":"162","author":"Li","year":"1999","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100780_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2500\/ajr.2008.22.3136","article-title":"Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells","volume":"22","author":"Ramanathan","year":"2008","journal-title":"Am J Rhinol"},{"issue":"26","key":"10.1016\/j.waojou.2023.100780_bib35","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.waojou.2023.100780_bib37","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/all.14964","article-title":"Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia","volume":"76","author":"Lommatzsch","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100780_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:15Z","timestamp":1761849975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1939455123000406"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100780","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100780"}}